twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2019
vol. 121
 
Share:
Share:
abstract:
Original paper

HTRA1 rs11200638 and ARMS2 rs10490924 gene polymorphisms and response to intravitreal anti-VEGF treatment in patients with exudative age-related macular degeneration

Agnieszka Kubicka-Trząska
1
,
Izabella Karska-Basta
1
,
Sylwia Dziedzina
2
,
Marek Sanak
2
,
Bożena Romanowska-Dixon
1

1.
Klinika Okulistyki i Onkologii Okulistycznej Katedry Okulistyki Uniwersytetu Jagiellońskiego Collegium Medicum w Krakowie Kierownik: prof. dr hab. n. med. Bożena Romanowska-Dixon
2.
Zakład Biologii Molekularnej i Genetyki Klinicznej II Katedry Chorób Wewnętrznych Uniwersytetu Jagiellońskiego Collegium Medicum w Krakowie Kierownik: prof. dr hab. n. med. Marek Sanak
Online publish date: 2019/06/05
View full text Get citation
 
PlumX metrics:
Aim
To analyze the correlation between HTRA1 rs11200638 and ARMS2 rs10490924 gene polymorphisms and the response to ranibizumab and bevacizumab in patients with age-related macular degeneration.

Material and methods
A hundred and four patients were enrolled. The response to treatment measured as the change of best corrected visual acuity and central retinal thickness from baseline was assessed at 4-week intervals for 6 months. No response to anti-VEGF therapy was defined as no improvement or deterioration of best corrected visual acuity ≥ 1 line (Snellen) and reduction in central retinal thickness ≤ 10% on optical coherence tomography after the loading phase.

Results
Most patients with age-related macular degeneration had AA genotype of HTRA1 rs11200638 polymorphism which presence increases the risk of age-related macular degeneration 12-fold as compared to patients negative for this genotype (p = 0.0028). The AA HTRA2 rs11200638 genotype demonstrated a tendency towards worse response to anti-VEGF therapy, however the difference was not significant. Among 22.11% of non-responders, 59.25% of patients had genotype AA of HTRA1 rs1100638. The genotype TT in ARMS2 rs10490924 polymorphism was associated with a risk of age-related macular degeneration increased 14-fold as compared to individuals negative for this genotype (p = 0.0000). There was no association between any of the ARMS2 rs10490924 genotypes and the response to anti-VEGF therapy.

Conclusions
The study demonstrated the associations between HTRA1 rs1100628 and ARMS2 rs10490924 polymorphisms and a significantly increased risk of age-related macular degeneration. There was no association between any of the studied HTRA1 and ARMS2 polymorphism genotypes and the anti-VEGF therapy results.

keywords:

HTRA1, ARMS2, genetic polymorphism, age-related macular degeneration

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.